Christine Fox Sells 7,924 Shares of Teva Pharmaceutical Industries (NYSE:TEVA) Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) EVP Christine Fox sold 7,924 shares of the company’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $31.67, for a total transaction of $250,953.08. Following the completion of the transaction, the executive vice president directly owned 84,905 shares of the company’s stock, valued at approximately $2,688,941.35. The trade was a 8.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Teva Pharmaceutical Industries Stock Up 1.3%

Shares of NYSE TEVA traded up $0.39 during midday trading on Monday, reaching $31.44. 11,093,245 shares of the company’s stock were exchanged, compared to its average volume of 9,695,220. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $37.35. The business’s fifty day moving average price is $33.01 and its two-hundred day moving average price is $26.32. The stock has a market capitalization of $36.15 billion, a PE ratio of 26.20, a price-to-earnings-growth ratio of 10.39 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The firm had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.36 billion. During the same quarter in the prior year, the business posted $0.71 earnings per share. Teva Pharmaceutical Industries’s revenue for the quarter was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently issued reports on TEVA. Bank of America lifted their price target on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Scotiabank raised their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the stock a “sector outperform” rating in a report on Thursday, January 29th. Piper Sandler reissued an “overweight” rating and issued a $41.00 target price (up from $40.00) on shares of Teva Pharmaceutical Industries in a research report on Wednesday, March 4th. JPMorgan Chase & Co. upped their target price on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Finally, Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 31st. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Teva Pharmaceutical Industries currently has a consensus rating of “Moderate Buy” and an average price target of $37.67.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of hedge funds have recently added to or reduced their stakes in the business. Aster Capital Management DIFC Ltd bought a new stake in Teva Pharmaceutical Industries during the fourth quarter valued at $25,000. Allworth Financial LP lifted its position in shares of Teva Pharmaceutical Industries by 53.8% in the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after buying an additional 329 shares during the last quarter. Grove Bank & Trust boosted its holdings in shares of Teva Pharmaceutical Industries by 300.0% in the 4th quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after buying an additional 750 shares during the period. EverSource Wealth Advisors LLC grew its position in shares of Teva Pharmaceutical Industries by 51.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after buying an additional 345 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd grew its position in shares of Teva Pharmaceutical Industries by 567.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,334 shares of the company’s stock valued at $42,000 after buying an additional 1,134 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.